skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Carbon C 14-labeled Ixazomib (Code C111566)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Carbon C 14-labeled Ixazomib

Definition: A radioconjugate comprised of the orally available reversible 20S proteasome inhibitor ixazomib and labeled with the isotope carbon C 14. Upon administration, the ixazomib moiety hydrolyzes and generates its active form, MLN2238, which inhibits the activity of the 20S catalytic core subunit of the proteasome. This blocks the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins. The accumulation of protein may disrupt various cell signaling pathways, induce apoptosis, and inhibit tumor growth. In addition, this agent targets tumor suppressor microRNA-33b (miR-33b). Labeling with the radioactive tracer carbon C 14 allows for evaluation of ixazomib's absorption, distribution, metabolism and excretion (ADME).

Display Name: Carbon C 14-labeled Ixazomib

Label: Carbon C 14-labeled Ixazomib

NCI Thesaurus Code: C111566 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL453974  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
[14C]-1,4-(R,S)-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic Acid
Carbon C 14-labeled Ixazomib

External Source Codes: 
PDQ Closed Trial Search ID 751947
PDQ Open Trial Search ID 751947 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C111566
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom